Wayfinder Bio develops a new class of orally available RNA-targeting medicines that prevent the production of harmful proteins by binding to their encoding mRNAs
Wayfinder Bio develops a new class of orally available RNA-targeting medicines that prevent the production of harmful proteins by binding to their encoding mRNAs. Their proprietary technology combines experimental and AI/ML screening to discover small molecules that target specific RNA pockets.